Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia

Pharmacogenomics

Volumn 15, Issue 8, 2014, Pages 1105-1116

  Ceppi, Francesco ^a   Langlois Pelletier, Chloé ^a   Gagné, Vincent ^a   Rousseau, Julie ^a   Ciolino, Claire ^a   Lorenzo, Samanta De ^a   Kevin, Kojok M ^a   Cijov, Diana ^a   Sallan, Stephen E ^b,c   Silverman, Lewis B ^b,c   Neuberg, Donna ^b   Kutok, Jeffery L ^d   Sinnett, Daniel ^a,e   Laverdière, Caroline ^a,e   Krajinovic, Maja ^a,e  

^a UNIVERSITY OF MONTREAL   (Canada)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

childhood leukemia; peripheral neurotoxicity; pharmacogenetics; polymorphisms; treatment outcome; vincristine

Indexed keywords

ACTIN; ALANINE; ARGININE; GLYCINE; MICROTUBULE ASSOCIATED PROTEIN 4; TUBULIN; VINCRISTINE; ABCB1 PROTEIN, HUMAN; ACTG1 PROTEIN, HUMAN; ACTIN BINDING PROTEIN; CAPG PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; MULTIDRUG RESISTANCE PROTEIN; NUCLEAR PROTEIN;

ACTG1 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CAPG GENE; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; GENE; GENE FUNCTION; GENETIC POLYMORPHISM; GENOTYPE; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MAP4 GENE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROPROTECTION; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHENOTYPE; PROMOTER REGION; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION INITIATION SITE; TUBB1 GENE; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GENETICS; INFANT; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD;

ACTINS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DISEASE-FREE SURVIVAL; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INFANT; MALE; MICROFILAMENT PROTEINS; NUCLEAR PROTEINS; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; VINCRISTINE;

EID: 84905499525     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.68     Document Type: Article

References (55)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J. Clin. Oncol. 29(5), 551-565 (2011).
2. Pui CH, Sandlund JT, Pei D et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 104(9), 2690-2696 (2004).
3. Gatta G, Capocaccia R, Stiller C, Kaatsch P, Berrino F, Terenziani M. Childhood cancer survival trends in Europe: a EUROCARE Working Group study. J. Clin. Oncol. 23(16), 3742-3751 (2005).
4. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat. Rev. Genet. 4(12), 937-947 (2003).
5. Yang JJ, Cheng C, Devidas M et al. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120(20), 4197-4204 (2012).
6. Rousseau J, Gagne V, Labuda M et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 118(22), 5883-5890 (2011).
7. Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100(10), 3832-3834 (2002).
8. Ansari M, Sauty G, Labuda M et al. Polymorphisms in multidrug ressistance-associated protein gene 4 is associated with outcome childhood acute lymphoblastic leukemia. Blood 114, 1383-1386 (2009).
9. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14(4), 567-572 (2000).
10. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat. Rev. Cancer 6(2), 117-129 (2006).
11. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Cancer, Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 329-372 (2001).
12. Gidding CE, Meeuwsen-de Boer GJ, Koopmans P, Uges DR, Kamps WA, de Graaf SS. Vincristine pharmacokinetics after repetitive dosing in children. Cancer Chemother. Pharmacol. 44(3), 203-209 (1999).
13. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10(3), 194-204 (2010).
14. Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M. Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. J. Biol. Chem. 278(46), 45082-45093 (2003).
15. Kavallaris M, Tait AS, Walsh BJ et al. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res. 61(15), 5803-5809 (2001).
16. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study. Proteomics 6(5), 1681-1694 (2006).
17. Verrills NM, Po'uha ST, Liu ML et al. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. J. Natl Cancer Inst. 98(19), 1363-1374 (2006).
18. Sun HQ, Kwiatkowska K, Wooten DC, Yin HL. Effects of CapG overexpression on agonist-induced motility and second messenger generation. J. Cell Biol. 129(1), 147-156 (1995).
19. Tsuruo T, Oh-Hara T, Saito H. Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562. Anticancer Res. 6(4), 637-641 (1986).
20. de Graaf SS, Bloemhof H, Vendrig DE, Uges DR. Vincristine disposition in children with acute lymphoblastic leukemia. Med. Pediatr. Oncol. 24(4), 235-240 (1995).
21. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem. 58, 137-171 (1989).
22. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13(2), 89-95 (2003).
23. Kim RB, Leake BF, Choo EF et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
24. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specificity. Science 315(5811), 525-528 (2007).
25. Nakamura T, Sakaeda T, Horinouchi M et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 71(4), 297-303 (2002).
26. Guilhaumou R, Solas C, Bourgarel-Rey V et al. Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity. Cancer Chemother. Pharmacol. 68(6), 1633-1638 (2011).
27. Dennison JB, Kulanthaivel P, Barbuch RJ, Renbarger JL, Ehlhardt WJ, Hall SD. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos. 34(8), 1317-1327 (2006).
28. Dennison JB, Jones DR, Renbarger JL, Hall SD. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes. J. Pharmacol. Exp. Ther. 321(2), 553-563 (2007).
29. Egbelakin A, Ferguson MJ, MacGill EA et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr. Blood Cancer 56(3), 361-367 (2011).
30. Moghrabi A, Levy DE, Asselin B et al. Results of the Dana- Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 109(3), 896-904 (2007).
31. Silverman LB, Gelber RD, Dalton VK et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 97(5), 1211-1218 (2001).
32. Silverman LB, Stevenson KE, O'Brien JE et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 24(2), 320-334 (2010).
33. Vrooman LM, Stevenson KE, Supko JG et al. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study - Dana-Farber Cancer Institute All Consortium Protocol 00-01. J. Clin. Oncol. 31(9), 1202-1210 (2013).
34. National Cancer Institute Common Terminology Criteria for Adverse Events. www.ctep.cancer.gov
35. Gagne V, Rousseau J, Labuda M et al. Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin. Cancer Res. 19(18), 5240-5249 (2013).
36. NCBI SNP database. www.ncbi.nlm.nih.gov/SNP
37. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
38. Kroetz DL, Pauli-Magnus C, Hodges LM et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 13(8), 481-494 (2003).
39. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1988).
40. Labuda D, Krajinovic M, Richer C et al. Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. Anal. Biochem. 275(1), 84-92 (1999).
41. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001).
42. Quanto (Version 1.2). http://biostats.usc.edu/Quanto.html
43. Aplenc R, Glatfelter W, Han P et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 122(2), 240-244 (2003).
44. Hartman A, van Schaik RH, van der Heiden IP et al. Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. Leuk. Res. 34(2), 154-159 (2010).
45. Guilhaumou R, Simon N, Quaranta S et al. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases. Cancer Chemother. Pharmacol. 68(5), 1191-1198 (2011).
46. Jamroziak K, Mlynarski W, Balcerczak E et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur. J. Haematol. 72(5), 314-321 (2004).
47. Stanulla M, Schaffeler E, Arens S et al. GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia. Int. J. Hematol. 81(1), 39-44 (2005).
48. Efferth T, Sauerbrey A, Steinbach D et al. Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int. J. Oncol. 23(2), 509-517 (2003).
49. Jamroziak K, Balcerczak E, Cebula B et al. Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. Pharmacol. Rep. 57(6), 882-888 (2005).
50. Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJ. MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother. Pharmacol. 64(1), 183-188 (2009).
51. Wolf SJ, Bachtiar M, Wang J, Sim TS, Chong SS, Lee CG. An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics. Pharmacogenomics J. 11(5), 315-325 (2011).
52. Choi KH, Chen CJ, Kriegler M, Roninson IB. An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell 53(4), 519-529 (1988).
53. Hubert T, Van Impe K, Vandekerckhove J, Gettemans J. The actin-capping protein CapG localizes to microtubule-dependent organelles during the cell cycle. Biochem. Biophys. Res. Commun. 380(1), 166-170 (2009).
54. Fairbrother WG, Yeh RF, Sharp PA, Burge CB. Predictive identification of exonic splicing enhancers in human genes. Science 297(5583), 1007-1013 (2002).
55. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res. 36(Database issue), D820-D824 (2008).